Clin2Atlas
AtlasCancersNeoplasms

Multiple myeloma

2Disease-modifyingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020252001 — Zoledronic acid anhydrous approved (FDA)2005 — Lenalidomide approved (FDA)2008 — Plerixafor approved (FDA)2009 — Carfilzomib approved (FDA)2013 — Pomalidomide approved (FDA)2015 — Elotuzumab approved (FDA)2015 — Daratumumab approved (FDA)2015 — Ixazomib citrate approved (FDA)2015 — Panobinostat approved (FDA)2019 — Selinexor approved (FDA)2020 — Isatuximab approved (FDA)2020 — Belantamab mafodotin approved (FDA)2021 — Melphalan flufenamide approved (FDA)2021 — Idecabtagene vicleucel approved (FDA)2022 — Teclistamab approved (FDA)2022 — Ciltacabtagene autoleucel approved (FDA)2023 — Talquetamab approved (FDA)2023 — Motixafortide acetate approved (FDA)2023 — Elranatamab approved (FDA)
2001: Drug approval — Zoledronic acid anhydrous approved (FDA). 2005: Drug approval — Lenalidomide approved (FDA). 2008: Drug approval — Plerixafor approved (FDA). 2009: Drug approval — Carfilzomib approved (FDA). 2013: Drug approval — Pomalidomide approved (FDA). 2015: Drug approval — Elotuzumab approved (FDA). 2015: Drug approval — Daratumumab approved (FDA). 2015: Drug approval — Ixazomib citrate approved (FDA). 2015: Drug approval — Panobinostat approved (FDA). 2019: Drug approval — Selinexor approved (FDA). 2020: Drug approval — Isatuximab approved (FDA). 2020: Drug approval — Belantamab mafodotin approved (FDA). 2021: Drug approval — Melphalan flufenamide approved (FDA). 2021: Drug approval — Idecabtagene vicleucel approved (FDA). 2022: Drug approval — Teclistamab approved (FDA). 2022: Drug approval — Ciltacabtagene autoleucel approved (FDA). 2023: Drug approval — Talquetamab approved (FDA). 2023: Drug approval — Motixafortide acetate approved (FDA). 2023: Drug approval — Elranatamab approved (FDA)

What's being tested now

2000: 2 trials started2001: 2 trials started2004: 2 trials started2006: 1 trials started2007: 1 trials started2008: 2 trials started2009: 3 trials started2010: 2 trials started2011: 2 trials started2012: 3 trials started2013: 2 trials started2014: 1 trials started2015: 6 trials started2016: 7 trials started2017: 10 trials started2018: 11 trials started2019: 23 trials started2020: 29 trials started2021: 45 trials started2022: 68 trials started2023: 95 trials started2024: 130 trials started2025: 160 trials started2026: 172 trials started2000201020202026172

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 750 active Multiple myeloma trials on Clin2 →

Related

Lip and oral cavity cancerNasopharynx cancerOther pharynx cancerEsophageal cancerStomach cancerColon and rectum cancerGallbladder and biliary tract cancerPancreatic cancerLarynx cancerTracheal, bronchus, and lung cancerMalignant skin melanomaSoft tissue and other extraosseous sarcomas

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.